top of page

Our History

Founders Seek to Improve the Standard of Care in Advanced Parkinson’s Disease

Grounded in Strong Science and Proven Expertise

We have a successful global history supported by a strong scientific foundation and proven clinical and commercial expertise. Our founders, Ulf Rosén and Roger Bolsöy from sister company Lobsor Pharmaceuticals, held leading executive roles in NeoPharma, Solvay and AbbVie during the development and commercialization of levodopa-carbidopa intestinal gel, which has become a recognized therapy for advanced Parkinson´s disease (APD) worldwide. Based on this experience and close collaboration with leading neurologists and patient advocacy organizations to identify unmet medical needs, in 2013 they developed a patented pharmaceutical gel formulation of carbidopa, entacapone and levodopa for intestinal infusion with the goal to improve the standard of care for APD.


Their therapeutic discovery, called Lecigon®, was first approved and launched in Sweden in 2019 where it has shown significant market uptake and patient satisfaction. Today, this innovative product has achieved success globally and is now approved and commercially available in the Nordic countries and select European territories, including Germany and Austria. Additionally, regulatory approval has recently been achieved in several of the remaining European member states where Lecigon is expected to be commercially launched over the next several months. In September 2020, STADA’s Britannia Pharmaceuticals acquired the commercial rights to Lecigon outside of North/South America, Taiwan and Japan.


In April 2021, Intrance Medical Systems Inc., a subsidiary of Sweden-based Intrance Holdings AB, formally established its U.S. operations with the goal to bring its novel treatment approach for late-stage Parkinson’s disease to additional markets where the company owns and controls all intellectual property and commercial rights. These markets include the U.S., Canada, Mexico, South America, Japan and Taiwan. In the U.S., we have  submitted an Initial New Drug (IND) application to the U.S. Food and Drug Administration (FDA) based upon clear regulatory guidance.

Spanning the Globe to Address Unmet Medical Needs in APD

Intrance appoints new VP of Business Development and strengthens focus on strategic partnerships >> Read More

Intrance completes $17 million Series A financing and appoints Ed Schutter to board 
>> Read More

Intrance Medical Systems raises USD $8 millon in Series A financing

>> Read More

Additional regulatory approvals for Lecigon® secured for several remaining European member states (by STADA’s Britannia Pharmaceuticals)

Intrance Medical Systems appoints CEO and begins building its U.S. management team >> Read More

Intrance Medical Systems formally establishes U.S. operations

Intrance Medical Systems completes IND submission for novel APD treatment to U.S. FDA

Lobsor Pharmaceuticals acquired by leading CNS specialty pharmaceutical company, STADA’s Britannia; commercial rights to Lecigon® for North/South America, Taiwan and Japan remain with Intrance

Additional approvals obtained in continental Europe, including Germany, the Netherlands, Belgium, Austria, Slovenia and Romania

>> Read More

Market authorization of Lecigon® secured in select European countries by Lobsor Pharmaceuticals >> Read More

Regulatory approval/market authorization for Lecigon® secured in Sweden by Lobsor Pharmaceuticals

Founders create Intrance Holdings AB as independent entity in Sweden and establish Intrance Medical Systems, Inc. as a wholly owned subsidiary

Initiate development of patented triple-drug combination APD treatment

Lobsor Pharmaceuticals established in Sweden

Founders create independent entity, Lobsor Holdings AB, in Sweden

bottom of page